|
業務類別
|
Biotechnology |
|
業務概覽
|
Camp4 Therapeutics Corp is a clinical-stage biopharmaceutical company pioneering the discovery and development of regulatory RNA-based therapeutics to upregulate gene expression and restore healthy protein levels to treat various genetic diseases. The company focuses on genetic diseases of the central nervous system and liver. Its pipeline products include CMP-CPS-001 and CMP-SYNGAP. The company operates as a single operating segment, R&D, which engages in the development ofa new class of RNA-based therapeutics to treat a broad range of genetic diseases. |
| 公司地址
| One Kendall Square, Building 1400 West, 3rd Floor, Cambridge, MA, USA, 02139 |
| 電話號碼
| +1 617 651-8867 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.camp4tx.com |
| 員工數量
| 48 |
| Mr. Joshua Mandel-Brehm |
President, Chief Executive Officer and Director |
美元 600.00K |
23/04/2026 |
| Dr. Yuri Maricich, M.D. |
Chief Medical Officer |
美元 500.00K |
23/04/2026 |
| Dr. Daniel Tardiff, PhD |
Chief Scientific Officer |
-- |
23/04/2026 |
| Ms. Kelly Gold |
Chief Financial Officer and Principal Accounting Officer |
美元 465.00K |
23/04/2026 |
| Mr. Steven H. Holtzman |
Independent Director |
-- |
23/04/2026 |
|
|
| Mr. Joshua Mandel-Brehm |
President, Chief Executive Officer and Director |
23/04/2026 |
| Dr. Douglas E. Williams,PhD |
Chairman of the Board |
23/04/2026 |
| Dr. Andrew J. Schwab, PhD |
Independent Director |
23/04/2026 |
| Dr. Murray W. Stewart, M.D. |
Director |
23/04/2026 |
| Dr. Richard A. Young,PhD |
Independent Director |
23/04/2026 |
| Mr. Steven H. Holtzman |
Independent Director |
23/04/2026 |
| Mr. Michael J. Higgins |
Independent Director |
23/04/2026 |
| Mr. Amir H. Nashat, PhD |
Independent Director |
23/04/2026 |
| Mr. Michael F. Maclean |
Director |
24/03/2026 |
|
|
|
|
